Pharma
Commented by Nico Popp on March 3rd, 2026 | 07:40 CET
Paradigm shift in oncological dermatology: Vidac Pharma as an innovator, what are Almirall and Biofrontera doing?
Oncological dermatology is on the cusp of a revolution that could fundamentally change our understanding of cancer treatment. Persistence Market Research estimates that the global market for the treatment of actinic keratosis will reach a volume of around USD 7 billion by 2026. Analysts expect the market to grow to between USD 11.1 and 14.45 billion by the mid-2030s. This momentum is driven by the aging global population, cumulative UV exposure due to changing leisure habits, and increased awareness of the dangers of skin cancer. Currently, established industry giants such as Almirall and Biofrontera dominate the standard of care for actinic keratosis with their proven products. However, Vidac Pharma marks the transition from merely combating symptoms to a revolutionary procedure in oncological dermatology. This makes the company an opportunity for growth-oriented investors seeking access to a completely new class of drugs in the field of metabolic oncology.
Read
Commented by Fabian Lorenz on March 2nd, 2026 | 07:40 CET
First Majestic Silver hits an all-time high! Could Silver Viper Minerals be next? Resistance at Bayer!
The silver rally is far from over, as the price of the precious metal has stabilized at a high level of USD 90 per ounce, enabling the industry to generate high revenues. First Majestic is an impressive example, with investors celebrating record figures that pushed the stock to a new all-time high last week. Similarly, Silver Viper Minerals is drawing attention, offering clear growth targets and fueling takeover speculation. The CEO made a convincing case at an investor conference last week, outlining the Canadians’ 2026 motto: “drill, drill, drill.” At the same time, the company aims to grow through acquisitions, likely ensuring an exciting news flow. Meanwhile, at Bayer, the focus is back on glyphosate. Recent optimism about an end to the saga had driven the stock higher, but now, resistance is emerging.
Read
Commented by Armin Schulz on February 17th, 2026 | 08:10 CET
Cancer Research as a Growth Driver: How Bayer, Vidac Pharma, and Pfizer can enrich your portfolio
Oncology will be put to the test for the pharmaceutical industry in 2026. Never before have so many highly specialized active ingredients been on the verge of market launch at the same time. While checkpoint inhibitors and targeted therapies are revolutionizing treatment, business models are shifting from broad-based approaches to precision medicine. But the reality remains complex: between medical advances, narrow patient groups, and pressure on prices, companies need to readjust. Current developments at Bayer, Vidac Pharma, and Pfizer show how three players with different strategies are responding to this change.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 11:20 CET
SHARE PRICE FIREWORKS! RENK and Novo Nordisk shares take off! Vidac Pharma next?
Share price fireworks at Novo Nordisk yesterday. The battered pharmaceutical stock rose by around 6%. After a weak outlook and the prospect of increasing competition for its blockbuster product, there was some positive news for a change: a competing product is not permitted to be sold in the key US market. RENK shares also rose significantly yesterday. Since last Thursday, the share price has risen by over 10%. Positive analyst commentary is increasing. Vidac Pharma is poised for a rally. The biotech company is working on an attractive oncology pipeline, has once again secured an important patent, and the stock is receiving tailwinds from its Xetra listing. Analysts see the potential for a multiplication.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 07:00 CET
Rheinmetall, Bayer, Avrupa Minerals: Stocks for Europe's independence in defense, pharmaceuticals, and raw materials!
Europe is working feverishly to achieve independence. This applies, among other things, to defense, raw materials, and medicines. Investors can profit from these three stocks. Avrupa Minerals is developing raw material projects in Finland, Portugal, and other countries, skillfully diversifying to reduce risks. The stock is still largely unknown, but this is likely to change soon. Rheinmetall is a basic investment, although there was a noticeable drop in its share price last week. Are expectations too high? At the beginning of 2025, there were hardly any expectations for Bayer. This made the comeback of the company and its stock all the more spectacular. Recently, positive study results have once again caused excitement. The next blockbuster is in the pipeline.
Read
Commented by Armin Schulz on February 6th, 2026 | 07:00 CET
Almonty Industries Surges, Novo Nordisk and PayPal Correct: Where Are the Entry Points?
The stock market is increasingly divided. While mining stocks are benefiting from geopolitical upheavals and the strategic race for raw materials, established market heavyweights are being punished at the slightest disappointment. This shift reflects the growing limits of globalization. Today, resilience beats efficiency. Three very different companies illustrate this new environment: tungsten producer Almonty Industries, pharmaceutical giant Novo Nordisk, and payment service provider PayPal. We analyze the current situation.
Read
Commented by Armin Schulz on February 5th, 2026 | 09:30 CET
SAP in free fall! RE Royalties soaring - and how is Bayer's turnaround progressing?
The stock market is divided. Established names are tumbling, while niche players are booming. Software giant SAP is facing a crisis of confidence after disappointing forecasts. Its share price slump highlights how unforgiving markets are toward stagnating growth. At the same time, a smaller name is attracting attention. RE Royalties is benefiting from the exploding demand for electricity from AI with its renewable energy business model and is attracting investors with generous dividends. In between, pharmaceutical giant Bayer is battling the legacy issues of a prolonged downturn and showing that its turnaround is increasingly gaining traction. We take a closer look at the current situation.
Read
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on January 30th, 2026 | 07:25 CET
The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma
It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.
Read